| Literature DB >> 36229796 |
Christine M Veenstra1, Katrina R Ellis2, Paul Abrahamse2, Kevin C Ward3, Arden M Morris4, Sarah T Hawley2.
Abstract
BACKGROUND: We investigated whether partner (spouse or intimate partner) engagement in colorectal cancer (CRC) surveillance is associated with patient receipt of surveillance.Entities:
Keywords: Colorectal cancer; Dyadic; Partner; Surveillance
Mesh:
Year: 2022 PMID: 36229796 PMCID: PMC9559022 DOI: 10.1186/s12885-022-10131-3
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.638
Domains of Partner-Reported Engagement in Colorectal Cancer (CRC) Surveillance
| Domain | Definition | Items | Cronbach’s α |
|---|---|---|---|
| Informed | Perception of being informed about the risks and benefits of surveillance care | Thinking about your partner’s follow-up care for CRC, do you feel that • Risks/benefits of follow-up care in general • Risks/benefits of follow-up imaging • Risks/benefits of follow-up colonoscopy/sigmoidoscopy • Risks/benefits of follow-up CEA blood tests | 0.82 |
| Involved | Extent of involvement in surveillance | Thinking about your partner’s follow-up care for CRC, • Help take your partner to follow-up appointments • Attend doctor appointments for follow-up • Take notes during doctor appointment • Help schedule follow-up appointments • Help keep track of follow-up appointments on a calendar • Remind your partner about follow-up appointments • Talk to your partner about follow-up care options • Share information with your partner from other sources about follow-up care | 0.90 |
| Satisfaction with involvement in surveillance | Please tell us how you feel about the following statements (5-point Likert scale from “Not at all” to “Very much”) • I am satisfied with the amount of involvement I have in my partner’s follow-up care • I would like to participate more in my partner’s follow-up care | 0.62 | |
| Aware | Awareness of patients’ preferences for surveillance | How aware are you about | N/A |
Fig. 1Flow of patients and partners into the study sample. *Patients recruited from the Georgia SEER registry were selected for survey mailing based on the indication that they were married/partnered as recorded in the registry data. Patients from the other study sites were mailed surveys without prior knowledge of their partnered status
Characteristics of Patients (n = 307) and Partners (n = 307)
| Patients | Partners | |
|---|---|---|
|
|
|
|
| Age, years | ||
51–64 | 36 (11.8) 128 (41.8) 142 (46.4) | 48 (16.2) 118 (39.9) 130 (43.9) |
| Gender | ||
Male Female | 195 (63.7) 111 (36.3) | 113 (37.4) 189 (62.6) |
| Race | ||
White Black Other | 262 (85.3) 23 (7.5) 22 (7.2) | 263 (85.7) 20 (6.5) 24 (7.8) |
| Education | ||
High school or less Some college College graduate | 70 (22.8) 104 (33.9) 133 (43.3) | 82 (27.0) 108 (35.5) 114 (37.5) |
| Annual Household Income | ||
<$40,000 $40,000-$89,999 Missing/Unknown | 55 (17.9) 95 (30.9) 116 (37.8) 41 (13.4) | N/A |
| Comorbid conditions | ||
0 1 or more | 87 (28.3) 220 (71.7) | 78 (25.4) 229 (74.6) |
| Patients’ primary cancer | ||
Colon Rectum Both/unknown | 187 (60.9) 40 (13.0) 80 (26.1) | N/A |
| Years since diagnosis | N/A | |
1–2 3–4 | 78 (26.4) 182 (61.5) 36 (11.2) | |
| Patient receipt of chemotherapy | ||
Yes No | 285 (94.7) 16 (5.3) | N/A |
| Patient receipt of radiation | N/A | |
Yes No | 102 (34.0) 198 (66.0) |
Fig. 2The distribution of scores for each domain of partner engagement is illustrated as follows: (a) Informed (range 0–4, mean score 3.33, standard deviation 1.18), (b) Extent of Involvement (range 1–5, mean score 3.58, standard deviation 1.03), (c) Satisfaction with Involvement (range 1–5, mean score 2.67, standard deviation 1.01), (d) Aware (range 1–5, mean score 4.34, standard deviation 0.79)
Bivariate Analyses of Domains of Partner-Reported Engagement
| Informed | Extent of Involvement | Satisfaction with Involvement | Aware | |||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| Age, years | 0.06 | 0.80 | 0.02 | 0.21 | ||||
51–64 | 3 (1.46) 3.35 (1.1) 3.46 (1.08) | 3.54 (1.05) 3.55 (1.04) 3.63 (1.04) | 2.34 (1.09) 2.65 (1) 2.84 (0.98) | 4.19 (0.82) 4.42 (0.8) 4.33 (0.77) | ||||
| Gender | 0.72 | < 0.01 | 0.15 | < 0.01 | ||||
Female Male | 3.37 (1.13) 3.29 (1.23) | 3.83 (0.99) 3.19 (1.01) | 2.75 (1.04) 2.55 (0.97) | 4.48 (0.68) 4.12 (0.91) | ||||
| Race | 0.07 | 0.23 | 0.04 | 0.32 | ||||
Black White Other | 2.81 (1.6) 3.39 (1.11) 3.06 (1.48) | 3.35 (1.38) 3.63 (1.02) 3.14 (0.87) | 2.1 (1.12) 2.73 (1) 2.5 (1.08) | 4.11 (1.08) 4.37 (0.76) 4.17 (0.92) | ||||
| Education | 0.03 | < 0.01 | 0.46 | < 0.01 | ||||
High school or less Some college College graduate | 3.66 (0.76) 3.29 (1.18) 3.17 (1.33) | 3.91 (0.95) 3.63 (1.01) 3.33 (1.07) | 2.73 (0.96) 2.59 (1.03) 2.72 (1.05) | 4.56 (0.66) 4.38 (0.78) 4.16 (0.85) | ||||
| Annual Household Incomea | 0.52 | 0.03 | 0.90 | 0.81 | ||||
<$40,000 $40,000-$89,999 | 3.23 (1.31) 3.4 (1.11) 3.35 (1.14) | 3.9 (1.02) 3.54 (1) 3.45 (1.06) | 2.65 (1.08) 2.71 (0.96) 2.66 (1.04) | 4.43 (0.8) 4.31 (0.79) 4.32 (0.8) | ||||
Comorbid conditions 0 | 3.21 (1.22) | 0.29 | 3.5 (1.1 | 0.52 | 2.77 (1.05) | 0.15 | 4.36 (0.73) | 0.90 |
| 1 or more | 3.39 (1.14) | 3.61 (1.02) | 2.65 (1.01) | 4.34 (0.82) | ||||
aMultiple imputation was used to assign household income values for the 13% of respondents who did not report it
Multivariable Regression Models of Patient-Reported Receipt of Colorectal Cancer Surveillance
| Receipt of cross-sectional imaging | Receipt of endoscopy | Receipt of CEA | Receipt of all surveillance components | |
|---|---|---|---|---|
|
|
|
|
| |
|
| ||||
| Informed | 0.96 (0.50–1.85) | 1.12 (0.76–1.65) | 1.10 (0.85–1.43) | 0.95 (0.73–1.24) |
| Extent of involvement | 1.23 (0.62–2.46) | 0.60 (0.34–1.03) | 0.75 (0.55–1.04) | 0.67 (0.48–0.93) |
| Satisfaction with Involvement | 0.92 (0.45–1.88) | 1.07 (0.66–1.72) | 1.17 (0.87–1.57) | 1.28 (0.95–1.73) |
| Aware | 1.46 (0.65–3.27) | 2.18 (1.15–4.12) | 0.83 (0.54–1.28) | 1.30 (0.91–2.04) |
| Annual Household Income | ||||
| <$40,000 | REF | REF | REF | REF |
| $40,000-$89,999 | 2.88 (0.62–13.30) | 4.16 (1.19–14.59) | 1.97 (0.92–4.21) | 2.47 (1.07–5.70) |
| 1.47 (0.31–7.04) | 1.36 (0.41–4.57) | 2.08 (0.94–4.59) | 2.03 (0.86–4.77) | |
|
| ||||
| Receipt of chemotherapy | ||||
| No | REF | REF | REF | REF |
| Yes | 4.84 (0.74–31.66) | 9.97 (1.78–55.70) | 0.91 (0.23–3.64) | 8.85 (0.98–80.08) |